Author(s): Santos NC, de Araujo LM, Canto GDL, Guerra ENS, Coelho MS & Borin MdF. | Publication Year: 2017
BACKGROUND: Data about harms or benefits associated with the consumption of aspartame, a non-nutritive sweetener worldwide consumed, is still controversial. This systematic review and meta-analysis of randomized controlled clinical trials aimed to assess the effect of aspartame consumption on metabolic parameters related to diabetes and obesity.
METHODS: The search was performed on Cochrane, LILACS, PubMed, SCOPUS, Web of Science databases and on a grey literature using Open Grey, Google Scholar and ProQuest Dissertations & Theses Global. Searches across all databases were conducted from the earliest available date up to April 13, 2016, without date and language restrictions. Pooled mean differences were calculated using a random or fixed-effects model for heterogeneous and homogenous studies, respectively.
RESULTS: Twenty-nine articles were included in qualitative synthesis and twelve, presenting numeric results, were used in meta-analysis. Fasting blood glucose (mmol/L), insulin levels (?U/mL), total cholesterol (mmol/L), triglycerides concentrations (mmol/L), high-density lipoprotein cholesterol (mmol/L), body weight (Kg) and energy intake (MJ) were considered as the main outcomes in subjects that consumed aspartame and results were presented as (mean difference; % Confidence Interval, range). Aspartame consumption was not associated with alterations on blood glucose levels compared to control (?0.03 mmol/L; 95% CI, ?0.21 to 0.14) or to sucrose (0.31 mmol/L; 95% CI, ?0.05 to 0.67) and on insulin levels compared to control (0.13 ?U/mL; 95% CI, ?0.69 to 0.95) or to sucrose (2.54 ?U/mL; 95% CI, ?6.29 to 11.37). Total cholesterol was not affected by aspartame consumption compared to control (?0.02 mmol/L; 95% CI, ?0.31 to 0.27) or to sucrose (?0.24 mmol/L; 95% CI, ?0.89 to 0.42). Triglycerides concentrations were not affected by aspartame consumption compared to control (0.00 mmol/L; 95% CI, ?0.04 to 0.05) or to sucrose (0.00 mmol/L; 95% CI, ?0.09 to 0.09). High-density lipoprotein cholesterol serum levels were higher on aspartame compared to control (?0.03 mmol/L; 95% CI, ?0.06 to ?0.01) and lower on aspartame compared to sucrose (0.05 mmol/L; 95% CI, 0.02 to 0.09). Body weight did not change after aspartame consumption compared to control (5.00 Kg; 95% CI, ?1.56 to 11.56) or to sucrose (3.78 Kg; 95% CI, ?2.18 to 9.74). Energy intake was not altered by aspartame consumption compared to control (?0.49 MJ; 95% CI, ?1.21 to 0.22) or to sucrose (?0.17 MJ; 95% CI, ?2.03 to 1.69).
CONCLUSIONS: Data concerning effects of aspartame on main metabolic variables associated to diabetes and obesity do not support a beneficial related to its consumption.
Evidence from clinical trials included in this systematic review shows that aspartame use does not promote weight gain and in some cases produces a modest weight loss, consistent with the caloric reduction associated with their presence in the diet, and contrary to the outcomes of the meta-analysis presented in this paper. This is also in line with findings of previous systematic reviews, such as De la Hunty et al., 2006, Miller and Perez, 2014, and Rogers et al., 2016.
Furthermore, the review concludes that aspartame consumption was not associated with alterations on blood glucose and insulin levels compared to control or to sucrose. Total cholesterol and triglycerides concentrations were not affected by aspartame consumption, while high-density lipoprotein cholesterol serum levels were higher on aspartame compared to control and lower on aspartame compared to sucrose.
Surprisingly, the authors conclude, “although there were no found deleterious effects associated with aspartame consumption on variables studied, there is no support for the recommendation of aspartame consumption as a sweetener with the aim of comply dietary requirements on diabetes and obesity control according to studies evaluated”, despite the fact that the beneficial effect of low calorie sweeteners on post-prandial glucose, compared to sugar-sweetened foods, is recognised as a health claim by EFSA, and the fact that randomised clinical trials and previous systematic reviews and meta-analysis support a modest weight loss when low calorie sweeteners are used to replace sugar.